Amphastar Pharmaceuticals (AMPH) Receivables (2013 - 2026)

Amphastar Pharmaceuticals' Receivables history runs 14 years deep, the most recent figure standing at $147.8 million for Q1 2026.

• On a quarterly basis, Receivables rose 2.22% year-over-year to $147.8 million in Q1 2026; TTM through Mar 2026 was $147.8 million, a 2.22% increase from a year earlier, with the FY2025 full-year figure at $143.6 million, up 5.33% from the prior year.
• Receivables rose to $147.8 million in Q1 2026 per AMPH's latest filing, from $143.6 million in the prior quarter.
• Across five years, Receivables topped out at $147.8 million in Q1 2026 and bottomed at $73.2 million in Q1 2022.
• The 5-year median for Receivables is $131.7 million (2024), against an average of $119.0 million.
• Across the five-year window, Receivables decreased 6.12% in 2022 and soared 53.93% in 2023, its largest moves.
• Year by year, Receivables stood at $88.8 million in 2022, then rose by 29.43% to $114.9 million in 2023, then rose by 18.57% to $136.3 million in 2024, then increased by 5.33% to $143.6 million in 2025, then climbed by 2.99% to $147.8 million in 2026.
• Per Business Quant, the three latest AMPH Receivables figures stand at $147.8 million (Q1 2026), $143.6 million (Q4 2025), and $147.3 million (Q3 2025).